Ikarian Capital, LLC Verona Pharma PLC Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $2 Million - $2.96 Million	-174,194 Reduced 46.41%	201,116 $2.91 Million
Q1 2024 May 15, 2024	BUY	$15.3 - $20.24 $119,982 - $158,722	7,842 Added 2.13%	375,310 $6.04 Million
Q4 2023 Feb 14, 2024	BUY	$11.94 - $20.47 $583,591 - $1 Million	48,877 Added 15.34%	367,468 $7.31 Million
Q3 2023 Nov 14, 2023	BUY	$16.3 - $22.09 $80,098 - $108,550	4,914 Added 1.57%	318,591 $5.19 Million
Q2 2023 Aug 14, 2023	BUY	$19.41 - $23.43 $1.65 Million - $1.99 Million	85,000 Added 37.17%	313,677 $6.63 Million
Q1 2023 May 15, 2023	SELL	$18.06 - $25.27 $477,759 - $668,492	-26,454 Reduced 10.37%	228,677 $4.59 Million
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $590,400 - $1.57 Million	-60,000 Reduced 19.04%	255,131 $6.67 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $13.59 $62,642 - $205,630	15,131 Added 5.04%	315,131 $193,000
Q2 2022 Aug 12, 2022	BUY	$3.55 - $5.06 $1.07 Million - $1.52 Million	300,000 New	300,000 $200,000

167

68.7M

704K

685K

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.